References
- Liversidge EM. (2002). Nanocrystals: Resolving pharmaceutical formulation issues associated with poorly water-soluble compounds In: Marty JJ, ed. Particles, Marcel Dekker, Orlando.
- Möschwitzer J, Achleitner G, Pomper H, Müller RH. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm, 58:615–9.
- Liversidge GG, Conzentino P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–13.
- Jinno JI, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, (2006). Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release, 111:56–64.
- Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19:921–5.
- Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 56:827–40.
- Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the Future. Adv Drug Deliv Rev, 47:3–19.
- Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, (2005). Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 31:319–29.
- Thies J, Müller BW. (1998). Size controlled production of biodegradable microparticles with supercritical gases. Eur J Pharm Biopharm, 45:67–74.
- Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm, 62:3–16.
- Liversidge GG, Cundy KC. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailabilty of nanocrystalline danazol in beagel dogs. Int J Pharm, 125:91–7.
- Krause KP, Müller RH. (2001). Production and characterisation of highly concentrated nanosuspensions by high pressure homogenization. Int J Pharm, 214:21–4.
- Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22:906–10.
- Möschwitzer J, Müller RH. (2006). Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm, 62:282–7.
- Sheu MT, Yeh CM, Sokoloski TD. (1994). Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm, 103:137–46.
- Palmeiri GF, Antonini I, Martelli S. (1996). Characterization and dissolution studies of PEG4000/fenofibrate solid dispersions. STP Pharm Sci, 6:188–94.
- Kocbek P, Baumgartner S, Krist J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 312:179–86.
- Granero GE, Ramachandran C, Amidon GL. (2005). Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev Ind Pharm, 31:917–22.
- Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 59:419–26.
- She ZY, Ke X, Ping QN, Xu BH, Chen LL. (2007). Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats. Chin Nat Med, 5:50–5.
- Kayser O. (2001). A new approach for targeting to Cryptosporidium parium using mucoadhesive nanosuspensions: Research and applications. Int J Pharm, 214:83–5.